WA-LISTED pharmaceutical group Pharmanet has announced that its subsidiary, Molecular Pharmacology Limited, has received approval for the commencement of human trials into the effectiveness of its Thermalife Cream and its analgesic and anti-inflammatory compound Tripeptofen.
The company believes the trials, which are for the purpose of evaluating the effect of the two products on pain and function, are a significant step towards achieving commercial sales of the cream.
